The Trypanocidal Drug Suramin and Other Trypan Blue Mimetics Are Inhibitors of Pyruvate Kinases and Bind to the Adenosine Site*
暂无分享,去创建一个
D. Auld | M. Walkinshaw | P. Michels | L. Fothergill-Gilmore | I. McNae | H. P. Morgan | Matthew W. Nowicki | W. Zhong
[1] Kun-Yi Hsin,et al. EDULISS: a small-molecule database with data-mining and pharmacophore searching capabilities , 2010, Nucleic Acids Res..
[2] Noel Southall,et al. Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase. , 2010, Bioorganic & medicinal chemistry letters.
[3] Kun-Yi Hsin,et al. An improved strategy for the crystallization of Leishmania mexicana pyruvate kinase. , 2010, Acta crystallographica. Section F, Structural biology and crystallization communications.
[4] Christopher P Austin,et al. Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. , 2010, Journal of medicinal chemistry.
[5] M. Walkinshaw,et al. Allosteric Mechanism of Pyruvate Kinase from Leishmania mexicana Uses a Rock and Lock Model* , 2010, The Journal of Biological Chemistry.
[6] E. Clercq. Antiviral drug discovery: ten more compounds, and ten more stories (part B). , 2009 .
[7] Regina Z. Cer,et al. IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding , 2009, Nucleic Acids Res..
[8] M. Walkinshaw,et al. Sulphate removal induces a major conformational change in Leishmania mexicana pyruvate kinase in the crystalline state. , 2008, Journal of molecular biology.
[9] R. McGeary,et al. Suramin: clinical uses and structure-activity relationships. , 2008, Mini reviews in medicinal chemistry.
[10] T. Souto-Padrón,et al. Effect of suramin on the human pathogen Candida albicans: implications on the fungal development and virulence. , 2007, FEMS Immunology & Medical Microbiology.
[11] Randy J. Read,et al. Phaser crystallographic software , 2007, Journal of applied crystallography.
[12] A. Jagielski,et al. Suramin-induced reciprocal changes in glucose and lactate synthesis in renal tubules contribute to its hyperglycaemic action. , 2006, European journal of pharmacology.
[13] Barbara M. Bakker,et al. Experimental and in Silico Analyses of Glycolytic Flux Control in Bloodstream Form Trypanosoma brucei* , 2005, Journal of Biological Chemistry.
[14] A. Mesecar,et al. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. , 2005, Biochemistry.
[15] Kevin Cowtan,et al. research papers Acta Crystallographica Section D Biological , 2005 .
[16] Zefeng Wang,et al. The Adenosine Analog Tubercidin Inhibits Glycolysis in Trypanosoma brucei as Revealed by an RNA Interference Library* , 2003, Journal of Biological Chemistry.
[17] Peter Briggs,et al. A graphical user interface to the CCP4 program suite. , 2003, Acta crystallographica. Section D, Biological crystallography.
[18] Eugene Krissinel,et al. The CCP4 molecular-graphics project. , 2002, Acta crystallographica. Section D, Biological crystallography.
[19] Mark C. Field,et al. Evidence for a non-LDL-mediated entry route for the trypanocidal drug suramin in Trypanosoma brucei. , 2002, Molecular and biochemical parasitology.
[20] Laurent R. Chiarelli,et al. Structure and Function of Human Erythrocyte Pyruvate Kinase , 2002, The Journal of Biological Chemistry.
[21] Daniel J Rigden,et al. The putative effector‐binding site of Leishmania mexicana pyruvate kinase studied by site‐directed mutagenesis , 2002, FEBS letters.
[22] I Lundström,et al. Suramin blocks nucleotide triphosphate binding to ribosomal protein L3 from Trypanoplasma borreli. , 2000, European journal of biochemistry.
[23] S. Phillips,et al. The structure of pyruvate kinase from Leishmania mexicana reveals details of the allosteric transition and unusual effector specificity. , 1999, Journal of Molecular Biology.
[24] J. Suko,et al. Suramin and suramin analogs activate skeletal muscle ryanodine receptor via a calmodulin binding site. , 1999, Molecular pharmacology.
[25] G. H. Reed,et al. Structure of the bis(Mg2+)-ATP-oxalate complex of the rabbit muscle pyruvate kinase at 2.1 A resolution: ATP binding over a barrel. , 1998, Biochemistry.
[26] S. S. Huang,et al. Suramin enters and accumulates in low pH intracellular compartments of v‐sis‐transformed NIH 3T3 cells , 1997, FEBS letters.
[27] G. Murshudov,et al. Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.
[28] A. IJzerman,et al. Suramin analogues as subtype-selective G protein inhibitors. , 1996, Molecular pharmacology.
[29] F. Opperdoes,et al. Pyruvate kinase of Leishmania mexicana mexicana. Cloning and analysis of the gene, overexpression in Escherichia coli and characterization of the enzyme. , 1994, Molecular and biochemical parasitology.
[30] F. Opperdoes,et al. Synthesis and activity of inhibitors highly specific for the glycolytic enzymes from Trypanosoma brucei. , 1993, Molecular and biochemical parasitology.
[31] J. Wilting,et al. Recent research on the biological activity of suramin. , 1993, Pharmacological reviews.
[32] E. Weinberger,et al. A pilot study of suramin in the treatment of progressive refractory follicular lymphomas. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] M. Willingham,et al. In vivo regulation of monomer-tetramer conversion of pyruvate kinase subtype M2 by glucose is mediated via fructose 1,6-bisphosphate. , 1991, The Journal of biological chemistry.
[34] R. Danesi,et al. Suramin, a novel antitumor compound , 1990, The Journal of Steroid Biochemistry and Molecular Biology.
[35] K. Huang,et al. Effects of suramin, an anti-human immunodeficiency virus reverse transcriptase agent, on protein kinase C. Differential activation and inhibition of protein kinase C isozymes. , 1990, The Journal of biological chemistry.
[36] F. Opperdoes,et al. Effects of various metabolic conditions and of the trivalent arsenical melarsen oxide on the intracellular levels of fructose 2,6-bisphosphate and of glycolytic intermediates in Trypanosoma brucei. , 1987, European journal of biochemistry.
[37] F. Opperdoes,et al. The phosphoglycerate kinases from Trypanosoma brucei. A comparison of the glycosomal and the cytosolic isoenzymes and their sensitivity towards suramin. , 1987, European journal of biochemistry.
[38] S. Matsushita,et al. Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. , 1984, Science.
[39] H A Krebs,et al. Cytosolic phosphorylation potential. , 1979, The Journal of biological chemistry.
[40] P. Zuurendonk,et al. Intramitochondrial and extramitochondrial concentrations of adenine nucleotides and inorganic phosphate in isolated hepatocytes from fasted rats. , 1978, European journal of biochemistry.
[41] P. Evans,et al. Scaling and assessment of data quality. , 2006, Acta crystallographica. Section D, Biological crystallography.
[42] W. Delano. The PyMOL Molecular Graphics System , 2002 .
[43] J. Fantini,et al. Suramin : a molecule with a broad spectrum of biological and therapeutic properties , 1997 .
[44] E. Eigenbrodt,et al. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. , 1992, Critical reviews in oncogenesis.
[45] F. Opperdoes. Compartmentation of carbohydrate metabolism in trypanosomes. , 1987, Annual review of microbiology.
[46] S. Subramanian,et al. Dye-ligand affinity chromatography: the interaction of Cibacron Blue F3GA with proteins and enzymes. , 1984, CRC critical reviews in biochemistry.
[47] A. Fairlamb,et al. Uptake of the trypanocidal drug suramin by bloodstream forms of Trypanosoma brucei and its effect on respiration and growth rate in vivo. , 1980, Molecular and biochemical parasitology.
[48] F. Hawking. Suramin: with special reference to onchocerciasis. , 1978, Advances in pharmacology and chemotherapy.
[49] W. Fischer,et al. Report on the Use of " Bayer 205 " in Africa. , 1922 .